Incorporated in Mar.'89 as a private limited company, Suven Pharmaceuticals (SPL) was converted into a public limited company in Jan.'95. It was promoted by Jasti Sudha Rani and Jasti Venkateswarlu, who is the present managing director. In Mar.'95, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. The company manufactures bulk drugs and drug intermediates -- theophylline, caffeine, nitroso compound, cyanoacetic acid, etc. SPL has a sizeable export turnover through the export of drug intermediates to Germany, Switzerland, Israel, Europe, etc. During 1999-2000, the company has acquired a small pilot plant in Jeedimetla Industrial Estate,Hyderabad. During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 has registered a growth of 71% over the previous year.The Profit After Tax(PAT) has also registered a growth of 325% over the previous year. The company has successfully achieved the re-certification of ISO 9002 during the year 2000-01. The company is planning to Modernize & Upgrade its R & D at Jeedimetla Industrial Estate.